Working… Menu

Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01679483
Recruitment Status : Completed
First Posted : September 6, 2012
Last Update Posted : May 31, 2017
Baxter Healthcare Corporation
Information provided by (Responsible Party):
Joo-Hyun Nam, Asan Medical Center

Brief Summary:
To compare the incidence of lymphocele and lymphatic ascites between patient who use versus who do not use FloSeal during lymph node dissection

Condition or disease Intervention/treatment Phase
Gynecologic Cancer Cervical Cancer Endometrial Cancer Ovarian Cancer Fallopian Tubal Cancer Drug: FloSeal application Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Study Start Date : September 2012
Actual Primary Completion Date : November 2015
Actual Study Completion Date : November 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: FloSeal group
This group will undergo appropriate cancer surgery for each patient with pelvic lymph node dissection +/- para-aortic lymph node dissection. At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
Drug: FloSeal application
At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.

No Intervention: No FloSeal group
All surgical procedures of control group is the same with study group except that Floseal is not applicated in control group.

Primary Outcome Measures :
  1. Incidence of lymphocele an lymphatic ascites [ Time Frame: within 1 year after surgery ]

Secondary Outcome Measures :
  1. Time interval from surgery to removal of closed drain system [ Time Frame: with 2 weeks after surgery ]
  2. Postoperative drain amount [ Time Frame: with 2 weeks after surgery ]
  3. Postoperative hospital stay [ Time Frame: within 2 weeks after surgery ]
  4. Postoperative bleeding incidence [ Time Frame: within 2 weeks after surgery ]
  5. Postoperative complication incidence [ Time Frame: within 1 month after surgery ]
  6. Quality of life [ Time Frame: within 1 year after surgery ]
  7. 2-year disease free survival and overall survival [ Time Frame: 2 years after surgery ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed primary cancer of the uterine cervix, uterine corpus, ovary, and fallopian tube
  • FIGO stage Cervical cancer: FIOG stage IA2-IIA2 Uterine cancer: FIGO stage I-III Ovarian and fallopian tubal cancer: FIGO stage I-IIIB
  • Patients who undergoing surgery including pelvic and/or para-aortic lymph node dissection
  • Patients with adequate bone marrow, renal and hepatic function:

WBC > 3,000 cells/mcl Platelets >100,000/mcl Creatinine <2.0 mg/dL Bilirubin <1.5 x normal and SGOT or SGPT <3 x normal

  • American Society of Anesthesiology Physical Status 0-1
  • Performance status of ECOG 0-2
  • Patient must be suitable candidates for surgery
  • Patients who have signed an approved Informed Consent

Exclusion Criteria:

  • Patients with a history of pelvic or abdominal radiotherapy;
  • Patients who are pregnant
  • Patients with contraindications to surgery;
  • Patients who are unfit for Surgery: serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator);
  • Patient's compliance and geographic proximity that do not allow adequate follow-up.
  • Patients who undergo only lymph node sampling

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01679483

Layout table for location information
Korea, Republic of
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center
Seoul, Korea, Republic of, 138-736
Sponsors and Collaborators
Asan Medical Center
Baxter Healthcare Corporation
Layout table for investigator information
Principal Investigator: Joo-Hyun Nam, M.D., Ph.D. Asan Medical Center
Layout table for additonal information
Responsible Party: Joo-Hyun Nam, Professor, Asan Medical Center Identifier: NCT01679483    
Other Study ID Numbers: FloSeal-LND
First Posted: September 6, 2012    Key Record Dates
Last Update Posted: May 31, 2017
Last Verified: May 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Neoplasms by Site
Genital Neoplasms, Female
Urogenital Neoplasms
Uterine Neoplasms
Uterine Diseases
Lymphatic Diseases